Assess whether a CMC change is a comparability or a new product (354769)

Situation

A CRL citing manufacturing, not efficacy put disproportionate reporting signal workbook in front of clinical-development physician in a biologics company planning a biosimilar pathway. This Pharma & Life Sciences / Clinical and Evidence Strategy close is a CMC change is from disproportionate reporting signal workbook, and the live options are A CMC change is a comparability, A new product.

Decision

Clinical-development physician in a biologics company planning a biosimilar pathway must choose A CMC change is a comparability / A new product using disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Disproportionate reporting signal workbook reads as A CMC change is a comparability once a CRL citing manufacturing, not efficacy is lined up to the same Pharma & Life Sciences population.
• Disproportionate reporting signal workbook is closer to A new product after a CRL citing manufacturing, not efficacy; A CMC change is a comparability would over-claim this Clinical and Evidence Strategy extract.
• A dual reading is still live in disproportionate reporting signal workbook for clinical-development physician in a biologics company planning a biosimilar pathway.
• Disproportionate reporting signal workbook is missing the fact clinical-development physician needs after a CRL citing manufacturing, not efficacy; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a CRL citing manufacturing, not efficacy and write the one fact that would move a CMC change is for clinical-development physician.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.